RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications

Omer Saeed, Antonio Lopez-Beltran, Kurt W. Fisher, Marina Scarpelli, Rodolfo Montironi, Alessia Cimadamore, Francesco Massari, Matteo Santoni, Liang Cheng

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The RAS family is among the most commonly mutated genes in all human malignancies including colon cancer. In normal cells, RAS proteins act as a link in the intracellular signal transduction initiated by binding of growth factors to cell membrane receptors mediating cell survival. RAS isoproteins have great morphological similarities, but despite that, they are thought to have different functions in different tissues. RAS mutations, as supported by several studies including animal models, have a role in the development and progression of colorectal cancer. The detection of RAS mutations in patients with colorectal carcinoma, specifically KRAS and NRAS, has significant clinical implications. It is currently recommended that patients with colon cancer who are considered for antiepidermal growth factor receptor monoclonal antibodies, get RAS mutation testing since only those with wildtype-RAS genes benefit from such treatment. Despite decades of research, there is currently no effective and safe treatment that directly targets RAS-mutated neoplasms. Multiple therapeutic approaches directed against RAS mutations are currently experimental, including a promising immunotherapy study using T-cells in patients with metastatic colon cancer.

Original languageEnglish (US)
JournalJournal of Clinical Pathology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Colorectal Neoplasms
Guidelines
Colonic Neoplasms
Mutation
Genes
Growth Factor Receptors
Therapeutics
Immunotherapy
Signal Transduction
Neoplasms
Cell Survival
Intercellular Signaling Peptides and Proteins
Animal Models
Monoclonal Antibodies
Cell Membrane
T-Lymphocytes
Research
Proteins

Keywords

  • braf
  • colorectal cancer
  • kras
  • microsatellite instability (msi)
  • molecular diagnostics
  • nras
  • personalized medicine

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

RAS genes in colorectal carcinoma : Pathogenesis, testing guidelines and treatment implications. / Saeed, Omer; Lopez-Beltran, Antonio; Fisher, Kurt W.; Scarpelli, Marina; Montironi, Rodolfo; Cimadamore, Alessia; Massari, Francesco; Santoni, Matteo; Cheng, Liang.

In: Journal of Clinical Pathology, 01.01.2018.

Research output: Contribution to journalArticle

Saeed, Omer ; Lopez-Beltran, Antonio ; Fisher, Kurt W. ; Scarpelli, Marina ; Montironi, Rodolfo ; Cimadamore, Alessia ; Massari, Francesco ; Santoni, Matteo ; Cheng, Liang. / RAS genes in colorectal carcinoma : Pathogenesis, testing guidelines and treatment implications. In: Journal of Clinical Pathology. 2018.
@article{e53718e3c3474b7786c2f3401bc88fc4,
title = "RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications",
abstract = "The RAS family is among the most commonly mutated genes in all human malignancies including colon cancer. In normal cells, RAS proteins act as a link in the intracellular signal transduction initiated by binding of growth factors to cell membrane receptors mediating cell survival. RAS isoproteins have great morphological similarities, but despite that, they are thought to have different functions in different tissues. RAS mutations, as supported by several studies including animal models, have a role in the development and progression of colorectal cancer. The detection of RAS mutations in patients with colorectal carcinoma, specifically KRAS and NRAS, has significant clinical implications. It is currently recommended that patients with colon cancer who are considered for antiepidermal growth factor receptor monoclonal antibodies, get RAS mutation testing since only those with wildtype-RAS genes benefit from such treatment. Despite decades of research, there is currently no effective and safe treatment that directly targets RAS-mutated neoplasms. Multiple therapeutic approaches directed against RAS mutations are currently experimental, including a promising immunotherapy study using T-cells in patients with metastatic colon cancer.",
keywords = "braf, colorectal cancer, kras, microsatellite instability (msi), molecular diagnostics, nras, personalized medicine",
author = "Omer Saeed and Antonio Lopez-Beltran and Fisher, {Kurt W.} and Marina Scarpelli and Rodolfo Montironi and Alessia Cimadamore and Francesco Massari and Matteo Santoni and Liang Cheng",
year = "2018",
month = "1",
day = "1",
doi = "10.1136/jclinpath-2018-205471",
language = "English (US)",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - RAS genes in colorectal carcinoma

T2 - Pathogenesis, testing guidelines and treatment implications

AU - Saeed, Omer

AU - Lopez-Beltran, Antonio

AU - Fisher, Kurt W.

AU - Scarpelli, Marina

AU - Montironi, Rodolfo

AU - Cimadamore, Alessia

AU - Massari, Francesco

AU - Santoni, Matteo

AU - Cheng, Liang

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The RAS family is among the most commonly mutated genes in all human malignancies including colon cancer. In normal cells, RAS proteins act as a link in the intracellular signal transduction initiated by binding of growth factors to cell membrane receptors mediating cell survival. RAS isoproteins have great morphological similarities, but despite that, they are thought to have different functions in different tissues. RAS mutations, as supported by several studies including animal models, have a role in the development and progression of colorectal cancer. The detection of RAS mutations in patients with colorectal carcinoma, specifically KRAS and NRAS, has significant clinical implications. It is currently recommended that patients with colon cancer who are considered for antiepidermal growth factor receptor monoclonal antibodies, get RAS mutation testing since only those with wildtype-RAS genes benefit from such treatment. Despite decades of research, there is currently no effective and safe treatment that directly targets RAS-mutated neoplasms. Multiple therapeutic approaches directed against RAS mutations are currently experimental, including a promising immunotherapy study using T-cells in patients with metastatic colon cancer.

AB - The RAS family is among the most commonly mutated genes in all human malignancies including colon cancer. In normal cells, RAS proteins act as a link in the intracellular signal transduction initiated by binding of growth factors to cell membrane receptors mediating cell survival. RAS isoproteins have great morphological similarities, but despite that, they are thought to have different functions in different tissues. RAS mutations, as supported by several studies including animal models, have a role in the development and progression of colorectal cancer. The detection of RAS mutations in patients with colorectal carcinoma, specifically KRAS and NRAS, has significant clinical implications. It is currently recommended that patients with colon cancer who are considered for antiepidermal growth factor receptor monoclonal antibodies, get RAS mutation testing since only those with wildtype-RAS genes benefit from such treatment. Despite decades of research, there is currently no effective and safe treatment that directly targets RAS-mutated neoplasms. Multiple therapeutic approaches directed against RAS mutations are currently experimental, including a promising immunotherapy study using T-cells in patients with metastatic colon cancer.

KW - braf

KW - colorectal cancer

KW - kras

KW - microsatellite instability (msi)

KW - molecular diagnostics

KW - nras

KW - personalized medicine

UR - http://www.scopus.com/inward/record.url?scp=85056582900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056582900&partnerID=8YFLogxK

U2 - 10.1136/jclinpath-2018-205471

DO - 10.1136/jclinpath-2018-205471

M3 - Article

C2 - 30425122

AN - SCOPUS:85056582900

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

ER -